New research has demonstrated that colour blindness may be capable of rescue by a simple sub-retinal injection of the genetic sequence for the missing photopigment.… Read More »Treating colour blindness with gene therapy shifts long held beliefs.
A new biomarker, “CCR3”, has been found to associate specifically with choroidal neovascularisation but not with normal retinal vasculature in research reported from the University… Read More »Paradigm shift in AMD biology may lead to new class of anti-angiogenics
Saving cone photoreceptors in a common form of retinitis pigmentosa paves the way for clinical studies
Researchers at the Institut National de la Sante et de la Recherche Medicale in Paris have reported the successful retention of central vision in an… Read More »Saving cone photoreceptors in a common form of retinitis pigmentosa paves the way for clinical studies
A gene therapy treatment of 12 patients between the ages of 8-44 years suffering RPE65-associated Leber’s Congenital Amaurosis (LCA) has been shown to improve vision… Read More »Phase 1 dose escalation study on gene therapy treatment for LCA shows importance of early treatment
Multi-centre Phase III clinical trial shows benefits of corticosteroid in reducing vision loss in ce
A multicenter, prospective, randomized clinical trial designed to compare 1-mg and 4-mg doses of intravitreal triamcinoclone with standard care for treatment of vision loss associated… Read More »Multi-centre Phase III clinical trial shows benefits of corticosteroid in reducing vision loss in ce
Researchers based at the Rotterdam Eye Hospital in the Netherlands have announced the first ever results reporting an association between the thickness of the retinal… Read More »Retinal nerve fiber layer (RNFL) thickness found to be associated with cognitive functioning.
Researchers based at Duke University Medical Centre, North Carolina have developed a new technology using spectral domain optical coherence tomography (SD-OCT) to produce a three-dimensional… Read More »New handheld imaging device finds early signs of retinopathy in premature infants
Gene Signal [www.genesignal.com] based in Lausanne, Switzerland, have reported interim results of a randomized Phase II clinical study on their lead drug candidate, GS-101. The… Read More »Gene Signal’s GS-101 results show safe and effective inhibition of blood vessel growth
Roche / Genentech sign licensing and development deal to access drug delivery formulation for Lucent
SurModics of Minnesota announced the completion of a License and Development Agreement with Roche / Genentech Inc for the use of SurModics’ proprietary microparticulate drug… Read More »Roche / Genentech sign licensing and development deal to access drug delivery formulation for Lucent